Literature DB >> 29893198

Utilization and Clinical Value of Diagnostic Modalities for Tuberculosis in a High HIV Prevalence Setting.

Stephanie Gati1, Rhoda Chetty2, Douglas Wilson2, Jacqueline M Achkar3,4,5.   

Abstract

Human immunodeficiency virus (HIV) infection is a major risk factor for the development of active tuberculosis (TB), one of the deadliest infectious diseases globally. The high mortality associated with the disease can be reduced by early diagnosis and prompt antituberculous treatment initiation. Facilities in TB-endemic regions are increasing the use of nucleic acid amplification (e.g., GeneXpert), which provides rapid results but may have suboptimal sensitivity in HIV-associated TB. Our objective was to evaluate the current practices for TB diagnosis at Edendale Hospital, a large regional hospital in KwaZulu-Natal, South Africa-a TB-endemic region with high HIV prevalence. In this cross-sectional study, all adult inpatients newly started on TB treatment at Edendale were identified over a 6-week period. Demographics, clinical information, diagnostic test results, and outcomes were documented. Pulmonary TB (PTB), extrapulmonary TB (EXTB), and PTB + EXTB were defined as disease evidence in the lungs, other organs, or both, respectively. Ninety-four cases were identified, of which 83% were HIV-associated. Only 30% of all TB patients were microbiologically confirmed, consisting of 7/16 (44%) HIV-uninfected and 21/78 (27%) HIV-infected TB patients. Smear microscopy and mycobacterial culture were seldom ordered. Ultrasound was performed in about one-third of suspected EXTB cases and was valuable in identifying abdominal TB. In this clinical setting with a high incidence of HIV-associated TB, TB diagnosis was more commonly based on clinical assessment and imaging results than on mycobacterial gold standard test confirmation.

Entities:  

Mesh:

Year:  2018        PMID: 29893198      PMCID: PMC6090324          DOI: 10.4269/ajtmh.17-0965

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  24 in total

1.  Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.

Authors:  Grant Theron; Jonny Peter; Richard van Zyl-Smit; Hridesh Mishra; Elizabeth Streicher; Samuel Murray; Rodney Dawson; Andrew Whitelaw; Michael Hoelscher; Surendra Sharma; Madhukar Pai; Robin Warren; Keertan Dheda
Journal:  Am J Respir Crit Care Med       Date:  2011-04-14       Impact factor: 21.405

2.  Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients.

Authors:  G Di Perri; A Cazzadori; S Vento; S Bonora; M Malena; L Bontempini; M Lanzafame; B Allegranzi; E Concia
Journal:  Tuber Lung Dis       Date:  1996-06

Review 3.  Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response.

Authors:  Jacqueline M Achkar; Elizabeth R Jenny-Avital
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

4.  Abdominal tuberculosis: sonographic diagnosis and treatment response in HIV-positive adults in rural South Africa.

Authors:  Tom Heller; Sam Goblirsch; Claudia Wallrauch; Richard Lessells; Enrico Brunetti
Journal:  Int J Infect Dis       Date:  2010-04-02       Impact factor: 3.623

5.  Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa.

Authors:  A Van Rie; L Page-Shipp; C F Hanrahan; K Schnippel; H Dansey; J Bassett; K Clouse; L Scott; W Stevens; I Sanne
Journal:  Int J Tuberc Lung Dis       Date:  2013-03       Impact factor: 2.373

Review 6.  Facing the crisis: improving the diagnosis of tuberculosis in the HIV era.

Authors:  Mark D Perkins; Jane Cunningham
Journal:  J Infect Dis       Date:  2007-08-15       Impact factor: 5.226

Review 7.  Meta-analysis: the association between HIV infection and extrapulmonary tuberculosis.

Authors:  Cho Naing; Joon Wah Mak; Mala Maung; Shew Fung Wong; Ani Izzuani Binti Mohd Kassim
Journal:  Lung       Date:  2012-11-23       Impact factor: 2.584

8.  Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.

Authors:  Lesley E Scott; Kerrigan McCarthy; Natasha Gous; Matilda Nduna; Annelies Van Rie; Ian Sanne; Willem F Venter; Adrian Duse; Wendy Stevens
Journal:  PLoS Med       Date:  2011-07-26       Impact factor: 11.069

9.  Sputum quality and diagnostic performance of GeneXpert MTB/RIF among smear-negative adults with presumed tuberculosis in Uganda.

Authors:  Amanda J Meyer; Collins Atuheire; William Worodria; Samuel Kizito; Achilles Katamba; Ingvar Sanyu; Alfred Andama; Irene Ayakaka; Adithya Cattamanchi; Freddie Bwanga; Laurence Huang; J Lucian Davis
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

10.  Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort.

Authors:  Stephen D Lawn; Andrew D Kerkhoff; Rosie Burton; Charlotte Schutz; Andrew Boulle; Monica Vogt; Ankur Gupta-Wright; Mark P Nicol; Graeme Meintjes
Journal:  BMC Med       Date:  2017-03-21       Impact factor: 8.775

View more
  2 in total

1.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

2.  Combining urine lipoarabinomannan with antibody detection as a simple non-sputum-based screening method for HIV-associated tuberculosis.

Authors:  Hiba Younis; Isabell Kerschbaumer; Jee-Young Moon; Ryung S Kim; Caroline J Blanc; Tingting Chen; Robin Wood; Steven Lawn; Jacqueline M Achkar
Journal:  PLoS One       Date:  2019-06-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.